Over the past several months, investors have gotten a few reminders that experimental vaccines can pose risks to trial participants. In turn, unexpected side effects and delays in the clinical trial process can punish stock prices. AstraZeneca's (NYSE: AZN) coronavirus vaccine trial is still on hold in the U.S. after a clinical trial participant experienced rare, severe, and potentially permanent side effects.
Each of these companies has serious potential to bring profits to investors, especially those with long time horizons.
The news signaled progress against the novel coronavirus that has infected more than 41 million globally, including 8 million Americans and comes 10 days before a U.S. presidential election that may hinge on plans https://www.reuters.com/article/us-usa-election/biden-warns-on-coronavirus-surge-trump-heads-to-florida-in-campaign-sprint-idUSKBN2781A4 to fight the pandemic. AstraZeneca, one of the leading vaccine developers, paused its U.S. trial on Sept. 6 after a report of a serious neurological illness, believed to be transverse myelitis, in a participant in the company's UK trial. J&J paused its large, late-stage trial last week after a study participant became ill.